Dr. Xanthopoulos heads the Stork Life Sciences program and has more than 23 years of experience as a serial entrepreneur in life sciences. He is a co-founder and Chairman & CEO of Shoreline Biosciences, a cell-therapy company. Prior to that he was the President & CEO of IRRAS AB (NASDAQ: IRRAS) where he led the listing of the company. He was the founding President & CEO of Regulus Therapeutics Inc. (NASDAQ: RGLS). Dr. Xanthopoulos also co-founded and served as President & CEO of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) until its acquisition by Roche.

Marios is a partner at both Stork Capital and Levant Capital where he leads healthcare investments. Marios has more than 20 years of experience in venture capital and private equity in the healthcare and life sciences sectors. He is currently a member of the Board of Directors of Shoreline Biosciences (U.S.), IRRAS (Sweden), and Senté (US). He has worked at TVM Capital, Advent International, and SG Capital Partners. Marios has an MBA from Columbia University.

Salameh has more than 20 years of experience in private equity and finance. He is a founding partner of Levant Capital and its CEO and a founding partner of Stork Capital and a member of the board. Salameh is currently a member of the Board of Directors of several of Levant Capital’s portfolio companies. Salameh worked at Goldman Sachs in New York and has a BS from Rensselaer Polytechnic Institute.

Philippe has more than 20 years of experience in private banking and private equity. He is a founding partner and Chairman of Stork Capital and a founding partner of Levant Capital and is currently a member of the Board of Directors of several of Levant Capital’s portfolio companies. Philippe worked at Merrill Lynch in New York and has an MBA from the Wharton School.